Literature DB >> 3034057

Mechanisms of action of and resistance to ciprofloxacin.

D C Hooper, J S Wolfson, E Y Ng, M N Swartz.   

Abstract

Ciprofloxacin and other newer quinolone antimicrobial agents exhibit increased potency and decreased frequency of spontaneous bacterial resistance in comparison with older analogues such as nalidixic acid. New and published observations on the mechanisms of action of and resistance to ciprofloxacin in Escherichia coli are presented and discussed. Genetic and biochemical studies have identified the A subunit of the essential bacterial enzyme DNA gyrase as a target of ciprofloxacin and other quinolones. For a series of quinolones, inhibition of purified DNA gyrase correlated with antibacterial activity. The bactericidal activity of ciprofloxacin and ofloxacin is, in contrast to that of certain other quinolones, somewhat less affected by rifampin and cell starvation, suggesting the existence of a site of drug action in addition to DNA gyrase. The frequency of selection of spontaneous single-step resistance mutants of E. coli was more than 100-fold lower with ciprofloxacin than with nalidixic acid. Strains highly resistant to ciprofloxacin could, nevertheless, be selected by serial passage on drug-containing agar. Two mutations contributing to this high level of resistance were analyzed. One, designated cfxA, conferred a 16-fold increase in drug resistance and mapped in a location consistent with a gyrA mutation; similar increases in resistance to ciprofloxacin were seen with gyrA mutations selected for resistance to other quinolones. The other mutation, cfxB, conferred pleiotropic resistance to ciprofloxacin, tetracycline, and chloramphenicol and appeared to be an allele of the multiple antibiotic resistance gene marA. The mutation cfxB was associated with a decreased amount of porin outer membrane protein OmpF, suggesting that drug permeation may occur in part through this channel. In summary, the A subunit of DNA gyrase is a target of ciprofloxacin and other quinolones. Ciprofloxacin resistance appears to occur both by mutation in this target and by alteration of drug permeation through the outer membrane of the cell.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034057

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  96 in total

1.  In vitro antibiotic resistance in bacterial keratitis in London.

Authors:  S J Tuft; M Matheson
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 3.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

4.  Prediction of resistance development against drug combinations by collateral responses to component drugs.

Authors:  Christian Munck; Heidi K Gumpert; Annika I Nilsson Wallin; Harris H Wang; Morten O A Sommer
Journal:  Sci Transl Med       Date:  2014-11-12       Impact factor: 17.956

5.  Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

Authors:  J S Wolfson; D C Hooper; E Y Ng; K S Souza; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

6.  Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid.

Authors:  N Moniot-Ville; J Guibert; N Moreau; J F Acar; E Collatz; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

7.  Quinolones and coumarins eliminate chloroplasts from Euglena gracilis.

Authors:  J Krajcovic; L Ebringer; J Polónyi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

8.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosa.

Authors:  R A Celesk; N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 10.  Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs Aging       Date:  1994-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.